Robertson, Rebecca
Amgen (United States)
2 papers on CoChat
Most cited papers
- Verified
The MDM2 inhibitor AMG 232 demonstrates robust antitumor efficacy and potentiates the activity of p53-inducing cytotoxic agents
Canon, J., Osgood, T., Olson, S. H., Saiki, A. Y., Robertson, R., Yu, D., Eksterowicz, J., Ye, Q., Jin, L., Chen, A., et al. (2015) · Molecular Cancer Therapeutics
Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer
Cited by 152
- Verified
MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways
Saiki, A. Y., Caenepeel, S., Yu, D., Lofgren, J. A., Osgood, T., Robertson, R., Canon, J., Su, C., Jones, A., Zhao, X., et al. (2014) · Oncotarget
Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer
Cited by 55
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free